Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 2 4Phase 3 2Phase 1/2 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Uterine Cervical Neoplasms 1Solid Tumor, Adult 1Recurrence 1Obesity 1Nutrition Disorders 1Neoplasms 1Motor Activity 1Hypertension 1Diabetes Mellitus 1Depression 1Cardiovascular Diseases 1Anus Neoplasms 1

Interventions

Dexamethasone 132Lenalidomide 58Bortezomib 56Calcium Dobesilate 44Melphalan 41carfilzomib 38pomalidomide 36Cyclophosphamide 35daratumumab 23belantamab mafodotin 21Peripheral Blood Stem Cell Transplantation 17ixazomib 16dexamethasone acetate 13Filgrastim 13Bendamustine Hydrochloride 13fludarabine phosphate 12fludarabine 12dexamethasone 21-phosphate 12Tacrolimus 12auricularum 11Whole-Body Irradiation 11liposomal doxorubicin 10iberdomide 10Prednisone 10venetoclax 9selinexor 9isatuximab 9Mycophenolic Acid 9pembrolizumab 8Cyclosporine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Multiple Myeloma × Therapeutics × Clear all
NCT01040026 2023-04-04

Expanded Natural Killer (NK) Cells for Multiple Myeloma Study

University Hospital, Basel, Switzerland

Phase 1/2 Completed
10 enrolled
Plasma cell

Multiple Myeloma

NCT01892293 2019-01-10

CT Antigen TCR-Engineered T Cells for Myeloma

Adaptimmune

Phase 1/2 Terminated
6 enrolled 10 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡